NCT05601219 - A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions

Solid Tumor, Adult

Interventions

DRUG

ADA-011

ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.

DRUG

PD(L)-1 inhibitor

PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.

Trial Locations (5)

Duke University, Durham

Florida Cancer Specialists, Orlando

The Christ Hospital, Cincinnati

HonorHealth, Scottsdale

Oregon Health & Science University, Portland